Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China Pharma Holdings (CPHI) Other Non-Current Liabilities: 2010-2022

Historic Other Non-Current Liabilities for China Pharma Holdings (CPHI) over the last 8 years, with Dec 2022 value amounting to $2.4 million.

  • China Pharma Holdings' Other Non-Current Liabilities was N/A to $2.2 million in Q1 2023 from the same period last year, while for Mar 2023 it was $2.2 million, marking a year-over-year change of. This contributed to the annual value of $2.4 million for FY2022, which is 26.85% up from last year.
  • As of FY2022, China Pharma Holdings' Other Non-Current Liabilities stood at $2.4 million, which was up 26.85% from $1.9 million recorded in FY2021.
  • China Pharma Holdings' Other Non-Current Liabilities' 5-year high stood at $2.7 million during FY2020, with a 5-year trough of $1.9 million in FY2021.
  • In the last 3 years, China Pharma Holdings' Other Non-Current Liabilities had a median value of $2.4 million in 2022 and averaged $2.3 million.
  • In the last 5 years, China Pharma Holdings' Other Non-Current Liabilities slumped by 31.44% in 2021 and then grew by 26.85% in 2022.
  • Yearly analysis of 5 years shows China Pharma Holdings' Other Non-Current Liabilities stood at $2.2 million in 2018, then climbed by 10.10% to $2.4 million in 2019, then climbed by 14.44% to $2.7 million in 2020, then plummeted by 31.44% to $1.9 million in 2021, then increased by 26.85% to $2.4 million in 2022.